Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia

Craig Wallington-Beddoe, Vicki Xie, Daochen Tong, Jason Powell, Alexander Lewis, Lorena Davies, Stuart Pitson, Kenneth Bradstock, Linda Bendall

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Sphingosine 1-phosphate (S1P) is generated from the phosphorylation of sphingosine by sphingosine kinase 1 (SPHK1) or sphingosine kinase 2 (SPHK2) (Pyne et al, 2016). Overexpression of SPHK1 has indisputable tumour-promotingproperties (Pyne & Pyne, 2010) and is associated with imatinib resistance in chronic myeloid leukaemia (Bonhoure et al, 2008; Marfe et al, 2011) and daunorubicin and cytarabine resistance in acute myeloid leukaemia cells (Sobue et al, 2008; Powell et al, 2017). We recently reported the involvement of SPHK2 in acute lymphoblastic leukaemia (ALL) (Wallington-Beddoe et al, 2014) and here we describe a rolefor SPHK1.
Original languageEnglish
Pages (from-to)443-447
Number of pages5
JournalBritish Journal of Haematology
Volume184
Issue number3
DOIs
Publication statusPublished - 1 Feb 2019

Keywords

  • Leukaemia
  • novel therapies
  • sphingosine kinase

Fingerprint Dive into the research topics of 'Identification of sphingosine kinase 1 as a therapeutic target in B-lineage acute lymphoblastic leukaemia'. Together they form a unique fingerprint.

Cite this